SUBSCRIBE
SUBSCRIBE

DealTalk: Battle for Actelion may be Rerun of Genzyme Saga

November 22, 2010 | 
1 min read
ZURICH (Reuters) - Jean-Paul Clozel, the ex-Roche (ROG.VX) scientist who founded Actelion (ATLN.VX) in 1997, is digging in to defend the Swiss biotech company in a battle that could mirror the fight for control of Genzyme (GENZ.O).
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
 · 
1 min read
 · 
Lori Ellis
US Dollar coin and EU currencies on weighing scale against Unated States and European Union flags as symbol of trade war, economic conflict. Selective focus on Dollar.
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
 · 
3 min read
 · 
Annalee Armstrong
Man in low poly style before important choice stock illustration, decision, triple, three
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
August 7, 2025
 · 
3 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH CRESSET
From Chat Bots to World Order: The Race for the 21st Century’s Operating System
August 7, 2025
 · 
1 min read
 · 
Lori Ellis